MAPK6 and breast cancer: The results showed no differences in cellular migration rates in either MDA-MB231 or BT549, indicating that ERK3 does not contribute to single-cell migration in a general chemoattractant setting in breast cancer (Figure 2B, Supplementary Figure S2B).